Novartis' Glivec receives positive review from EMEA

03/20/2009 | Reuters

The European Medicines Agency backed the use of Glivec, a cancer drug from Novartis AG, to prevent relapse in patients who underwent surgery for gastrointestinal stromal tumors. The company is seeking to promote wider use of Glivec as a first-line treatment for GIST.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Governmental Programs
Bluegrass Family Health
Lexington, KY
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA